Fig. 5
From: mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers
Sirolimus treatment reduced cancer progression markers (A) Representative mammary tissue section images (left) from paired pre- and post-treatment samples show expression of cytoplasmic & nuclear p16 protein in normal ducts (n = 12) and DCIS lesions (n = 12). Scale bar, 100 µm. Cytoplasmic p16 protein expression was quantified in pre- and post-sirolimus treated patients in normal (upper right) and DCIS (bottom right) tissue. (B) COX2 protein staining by IHC and quantitative expression analysis in normal (n = 21) and DCIS tissues (n = 17) from pre- and post-treatment samples. Statistical analysis was performed by 2-way ANOVA. Scale bar, 100 µm